Hormonaly.ai
Evidence OS for modern medicine with 24 AI agents synthesizing clinical answers from PubMed studies.
Website: https://hormonaly.ai/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Hormonaly.ai |
| Tagline | Evidence OS for modern medicine with 24 AI agents synthesizing clinical answers from PubMed studies |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology Type | AI / Machine Learning |
| Founding Team | Fady Hannah-Shmouni, MD FRCPC |
Links
PUBLIC
- Website: https://hormonaly.ai/
- Product (Copilot): https://hormonaly.ai/copilot
- Product (Lab): https://hormonaly.ai/lab
- Founder LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/
- Instagram: https://www.instagram.com/hormonaly.ai/
- Founder X / Twitter: https://x.com/drshmouni
Executive Summary
PUBLIC
Hormonaly.ai is positioning itself as a clinical-evidence operating system for peptide and hormone medicine, a sub-specialty that has grown rapidly in private practice but lacks the structured, GRADE-rated decision support that exists in larger fields like oncology or cardiology. The company describes its product as a set of 24 specialized AI agents that synthesize answers from more than 10,000 PubMed studies, returning citations and protocols in under 100 milliseconds [Hormonaly.ai]. The founder, Dr. Fady Hannah-Shmouni, is an endocrinologist and geneticist whose public record includes a principal investigator role in the Stratakis Laboratory at the National Institutes of Health and a clinical professorship at the University of British Columbia [Erdheim-Chester Disease Foundation]. According to a LinkedIn post under his account, the platform delivers 631 GRADE-rated protocols built for clinical workflows [LinkedIn]. No funding round, headquarters, founding year, or institutional investor has been disclosed in any source captured for this report, which places Hormonaly squarely at the pre-institutional stage from a public-data standpoint.
The most relevant near-term signal for investors will be the first third-party validation of the platform, whether that arrives as a clinic partnership, a published study using the protocols, or a priced funding round. Over the next 12 to 18 months, the questions that matter are whether the product converts the founder's domain authority into a paying provider base, and whether the company assembles the engineering and regulatory bench that an evidence-grade clinical tool eventually requires.
Data Accuracy: YELLOW -- Founder credentials cross-confirmed across LinkedIn, the Erdheim-Chester Disease Foundation bio, and Yahoo Finance; product claims rely on the company's own surfaces.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | SaaS |
| Industry / Vertical | Healthtech, clinical decision support |
| Technology Type | AI / Machine Learning, agentic systems |
| Founding Team | Solo clinician founder of record |
Company Overview
PUBLIC
Hormonaly.ai presents itself as an "evidence OS for modern medicine" focused initially on peptide and hormone therapy, two areas where prescribing practice has run ahead of consolidated clinical guidance [Hormonaly.ai]. The company's three public surfaces (the marketing site, a Copilot product page, and a Lab page) describe a platform that ingests randomized controlled trials, regulatory updates, and emerging compound data, then routes them through 24 agents tuned to clinical workflows [Hormonaly.ai]. The founding year, legal entity, and headquarters city are not disclosed on any captured surface.
The founder of record, Dr. Fady Hannah-Shmouni, is a board-certified endocrinologist whose biography includes service as associate program director of the NIH Inter-Institutes Endocrinology and Metabolism Fellowship, principal investigator on two NICHD protocols covering primary aldosteronism in Black patients and creatine transporter deficiency in males, and a current clinical professorship at the University of British Columbia [Erdheim-Chester Disease Foundation]. He was also recently named to the Medical Advisory Board of Science & Humans, a Canadian hormone-therapy clinic group [Yahoo Finance]. Public commentary from Hannah-Shmouni on podcasts including Mizter Rad, PHAMCAST, and Leaders On Purpose has centered on personalized medicine, the shift from "sickcare" to proactive health management, and the role of AI as a clinician-facing tool [Mizter Rad Show; PHAMCAST; Leaders On Purpose Podcast].
Milestones beyond the platform's existence are difficult to date from public sources. The earliest LinkedIn posts captured under the Hormonaly name are from late 2024, with additional product-positioning posts continuing into 2025 [LinkedIn]. No press release, accelerator cohort, or priced funding announcement has been identified.
Data Accuracy: YELLOW -- Founder career history confirmed across two independent biographical sources; corporate formation details not publicly available.
Product and Technology
MIXED
The product is described publicly as an AI operating system for peptide and hormone medicine, built around evidence-based protocols, real-time citations, and clinical-grade reasoning [PUBLIC] [Hormonaly.ai]. The marketing copy specifies a corpus of more than 10,000 PubMed studies and a response latency of under 100 milliseconds, with answers tagged using the GRADE framework that clinicians use to weigh evidence quality [PUBLIC] [Hormonaly.ai]. A LinkedIn post attributed to the founder adds the figure of 631 GRADE-rated protocols delivered through the agent layer [PUBLIC] [LinkedIn].
The 24-agent architecture is the most distinctive design choice. Rather than a single chat interface over a medical corpus, Hormonaly's public materials describe specialized agents mapped to clinical workflow steps, which is consistent with a broader trend in healthtech toward task-decomposed AI rather than monolithic chatbots [Hormonaly.ai]. The Copilot surface is positioned for use by healthcare providers at the point of care, and the Lab surface appears to be the protocol and evidence library [Hormonaly.ai]. The underlying model layer, retrieval pipeline, and any fine-tuning regime are not disclosed publicly, and no engineering job postings have been surfaced that would allow inference of the stack.
What is not yet public is equally relevant. There is no captured information about HIPAA or PIPEDA posture, no SOC 2 attestation referenced on the marketing site, no published clinical validation study, and no named EHR integration. For a tool that synthesizes guidance for prescribing decisions, those artifacts will eventually be table stakes for adoption inside any organized health system, even if they are less critical for the cash-pay peptide and hormone clinics that appear to be the initial wedge.
Data Accuracy: ORANGE -- All product specifics derive from company-controlled surfaces; no independent technical review or customer reference has been located.
Market Research and Opportunity
PUBLIC
The market that matters here is not "AI in healthcare" in the abstract, it is the narrower and faster-moving category of clinical decision support for cash-pay longevity, hormone, and peptide medicine, a segment whose prescribing volume has expanded sharply alongside GLP-1 awareness and the broader wellness-medicine boom.
No third-party TAM report specific to peptide and hormone clinical decision support has been captured for this analysis, so any sizing here would be inference rather than evidence. What can be said with citation is that seed-stage capital in AI-adjacent verticals has continued to flow in 2025, with Crunchbase reporting that seed rounds in the $10 million to $50 million band grew roughly 20 percent year over year and that AI is reshaping early-stage investment patterns [Crunchbase, 2025]. That funding environment is favorable for a company like Hormonaly that fits the profile investors are currently writing checks against: vertical AI, clinician-led, agentic architecture.
Demand drivers on the clinical side are easier to name than to size. The growth of direct-to-consumer hormone optimization clinics, the regulatory tightening around compounded GLP-1s, and the expanding off-label use of peptides have all increased the prescribing surface area where structured evidence is thin and clinician liability is real. Hannah-Shmouni's own podcast commentary has framed the transition from reactive sickcare to proactive longevity medicine as a structural shift rather than a fad [Leaders On Purpose Podcast; Mizter Rad Show]. Adjacent and substitute markets include general-purpose clinical reference tools (UpToDate, DynaMed), retrieval-augmented medical chat products built on general LLMs, and the in-house protocol libraries that larger telehealth chains develop for their own prescribers.
The regulatory backdrop deserves a flag. Clinical decision support software in the United States sits on a spectrum from non-regulated educational tools to FDA-regulated Software as a Medical Device, depending on whether outputs drive specific patient decisions and whether clinicians can independently review the basis for those outputs. Hormonaly's emphasis on real-time citations and GRADE ratings is consistent with the design pattern that has historically kept similar tools outside the device-regulation perimeter, but that boundary is fact-specific and worth monitoring.
| Metric | Value | Source |
|---|---|---|
| PubMed studies in corpus | 10,000+ | [Hormonaly.ai] |
| GRADE-rated protocols delivered | 631 | [LinkedIn] |
| Specialized AI agents | 24 | [Hormonaly.ai] |
| 2025 seed deals $10M-$50M, YoY growth | ~20% | [Crunchbase, 2025] |
The table makes clear that the substantive numbers about Hormonaly itself are product-spec figures rather than commercial metrics, which is consistent with a company that has not yet chosen to disclose traction.
Data Accuracy: YELLOW -- Funding-environment data confirmed by Crunchbase; no third-party market-sizing report specific to the company's wedge is publicly available.
Competitive Landscape
MIXED
Hormonaly enters a competitive field where no single player owns evidence-grade decision support for peptide and hormone medicine, but where several adjacent categories have credible claims on the same clinician's attention.
Three categories are worth distinguishing. The first is the established clinical reference layer, dominated by Wolters Kluwer's UpToDate and EBSCO's DynaMed, which clinicians already pay for and trust but which lag in coverage of off-label peptide protocols and emerging compounds. The second is the new wave of generalist medical AI, including products like OpenEvidence and Glass Health, which apply LLMs to broad clinical questions and are racing to add specialty depth. The third is the in-house protocol stack that vertically integrated hormone and longevity clinics, including the Science & Humans group that recently added Hannah-Shmouni to its Medical Advisory Board, build for their own prescribers [Yahoo Finance].
Where Hormonaly has a defensible edge today is founder-channel credibility in a niche where credibility compounds. Hannah-Shmouni's NIH research record and UBC professorship give the product a clinical voice that a generalist medical-AI startup cannot easily replicate, and the agentic architecture (24 task-specific agents rather than one chat box) is a more defensible product story than a thin wrapper over a foundation model [Erdheim-Chester Disease Foundation; Hormonaly.ai]. That edge is real but perishable: if a generalist player like OpenEvidence builds out a peptide and hormone module with comparable GRADE rigor, the differentiation narrows to dataset curation and clinician trust rather than core technology.
Where Hormonaly is most exposed is distribution and integration. UpToDate is sold through institutional licenses and embedded in EHR workflows, an entry point a small startup cannot match in the near term. The longevity clinic chains that represent the natural early customer base are themselves consolidating and have an incentive to build proprietary protocol libraries rather than pay a third party. Over the next 18 months, the most plausible scenario is that Hormonaly wins if it can convert one or two named cash-pay clinic chains into reference customers and publish a case study with retention or prescribing-quality metrics. The losing scenario is one in which a generalist medical-AI competitor with more capital ships a peptide module first and absorbs the category before Hormonaly raises an institutional round.
Data Accuracy: ORANGE -- Competitor categories named from analyst knowledge of the space; no head-to-head comparison data has been published by Hormonaly or third parties.
Opportunity
PUBLIC
If Hormonaly executes, the prize is to become the default evidence layer for a fast-growing slice of cash-pay medicine that the incumbent clinical reference tools have under-served.
The headline opportunity. The single largest outcome Hormonaly could plausibly reach is to become the canonical clinical decision-support tool for the peptide, hormone, and longevity-medicine segment, the same role UpToDate plays for hospital-based internists. That outcome is reachable, not aspirational, because the segment is large enough to support a focused vendor, the incumbent reference tools are weakest precisely in off-label and emerging-compound coverage, and the founder's clinical authority shortens the trust-building cycle that usually slows medical software adoption [Erdheim-Chester Disease Foundation; Hormonaly.ai]. The 631 GRADE-rated protocols already published, if accurate, represent a head start on the curation work that any competitor would need to replicate [LinkedIn].
Growth scenarios
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinic-chain reference customer | A named longevity or hormone clinic group adopts Hormonaly as its in-workflow evidence tool | Founder's advisory role at Science & Humans converts into a commercial pilot | Direct relationship already exists [Yahoo Finance] |
| Specialty-society endorsement | A hormone or anti-aging medicine society lists Hormonaly's protocols as a recommended reference | Publication of a peer-reviewed validation study comparing Hormonaly outputs to expert consensus | Founder has a peer-reviewed publication record at NIH that supports such a study [Erdheim-Chester Disease Foundation] |
| Vertical platform expansion | The 24-agent architecture extends from peptide and hormone medicine into adjacent specialties such as metabolic or rare endocrine disease | A second clinician co-founder or specialty lead joins to own a new vertical | Agentic architectures are inherently extensible, and seed capital in vertical AI is available [Crunchbase, 2025] |
All three scenarios are concrete and named rather than hypothetical, but each depends on a specific catalyst that has not yet been publicly reported.
What compounding looks like. The flywheel for an evidence-OS business is straightforward in theory and difficult in practice. Each new protocol curated raises the switching cost for existing users and lowers the marginal cost of acquiring the next user in the same specialty. Each clinician who cites a Hormonaly-sourced protocol in a chart note or a patient handout extends distribution at zero marginal cost. If the company can convert clinician usage into a contributed-protocol workflow (clinicians submitting their own protocols for GRADE review), it gains a data moat that pure LLM products cannot replicate by retrieval alone. None of that flywheel has been publicly evidenced yet, it is the design pattern the product appears to be built for.
The size of the win. A useful comparable, labelled as scenario rather than forecast, is the clinical reference category itself. Wolters Kluwer's Health division, which houses UpToDate, generated EUR 1.7 billion in 2023 revenue across a broader product set, and clinical decision support specifically has been valued by acquirers at high single-digit revenue multiples in past transactions. A vertical evidence-OS that captures even a small share of the cash-pay longevity-medicine prescriber base could plausibly support a nine-figure enterprise value if the clinic-chain scenario above plays out (scenario, not a forecast). The path from a single-founder company with no disclosed funding to that outcome is long and gated by hires, capital, and clinical validation that have not yet been reported, but the ceiling is high enough to justify investor attention at the current stage.
Data Accuracy: YELLOW -- Founder relationship to Science & Humans confirmed by Yahoo Finance; scenario sizing is explicitly labelled as analyst scenario rather than disclosed plan.
Sources
PUBLIC
[Hormonaly.ai] Hormonaly.ai - The Evidence OS | https://hormonaly.ai/
[Hormonaly.ai] Hormonaly.ai - AI OS for Peptide & Hormone | https://hormonaly.ai/copilot
[Hormonaly.ai] Hormonaly.ai - The Evidence OS (Lab) | https://hormonaly.ai/lab
[LinkedIn] Fady Hannah-Shmouni, MD FRCPC - Hormonaly | https://www.linkedin.com/in/fady-hannah-shmouni/
[LinkedIn] Hormonaly AI Platform for Evidence-Based Medicine | https://www.linkedin.com/posts/fady-hannah-shmouni_hormonaly-is-an-agentic-based-clinical-evidence-activity-7431945492172943360-O3Kk
[LinkedIn] Hormonaly AI Clinical OS for Evidence-Based Peptide & Hormone | https://www.linkedin.com/posts/fady-hannah-shmouni_evidencebasedmedicine-peptides-hormonetherapy-activity-7421917834009776129-Hy19
[LinkedIn] Hormonaly.ai - The Evidence OS (Philippe Gerwill post) | https://www.linkedin.com/posts/philippegerwill_hormonalyai-evidence-based-peptide-activity-7398246804150067200-KCky
[Erdheim-Chester Disease Foundation] Fady Hannah-Shmouni, MD, DABIM, FRCPC - Webinar Bio | https://www.erdheim-chester.org/wp-content/uploads/2021/02/Hannah-Shmouni-Fady-Webinar-Bio.pdf
[Loop Frontiers] Fady Hannah-Shmouni, MD FRCPC - Profile | https://loop.frontiersin.org/people/286065/overview
[Yahoo Finance] Science & Humans Welcomes Dr. Fady Hannah-Shmouni to Medical Advisory Board | https://finance.yahoo.com/news/science-humans-h-welcomes-esteemed-225000426.html
[Mizter Rad Show] Dr. Fady Hannah-Shmouni: Personalized Medicine and the Future of Aging | https://www.mizter-rad.com/episodes/44-aging-by-choice-dr-hannah-schmouni
[PHAMCAST] Dr. Fady Hannah-Shmouni (Part 2) | https://podcasts.apple.com/ca/podcast/dr-fady-hannah-shmouni-part-2/id1700393383?i=1000665000074
[PHAMCAST] Dr. Fady Hannah-Shmouni (Part 3) | https://open.spotify.com/episode/2UnZfmlKpc8BszIIVbE69u
[Leaders On Purpose Podcast] Episode 47 - Dr. Fady Hannah-Shmouni: Be The CEO Of Your Health | https://open.spotify.com/episode/1wDp16c30HK04bG3J8up8E
[X (Twitter)] Fady Hannah-Shmouni, MD FRCPC (@DrShmouni) | https://x.com/drshmouni
[Crunchbase, 2025] Seed Funding Hasn't Stalled, But It's Skewing Larger | https://news.crunchbase.com/venture/seed-funding-skewing-larger-ai-competitive-data/
Articles about Hormonaly.ai
- Hormonaly.ai Wants Every Hormone Clinician Citing PubMed in Under 100 Milliseconds — Endocrinologist Fady Hannah-Shmouni is building 24 AI agents to deliver GRADE-rated protocols for peptide and hormone medicine.